Literature DB >> 8340195

In vitro susceptibility of dermatophytes to antifungal drugs: a comparison of two methods.

A B Macura1.   

Abstract

BACKGROUND: There is an evidence that some fungal strains are resistant to certain antimycotic drugs with resulting therapeutic failures. Unlike testing of antibacterial agents, the activity of these drugs against the given fungal strains is not tested routinely. The paper presented is an approach to such a procedure.
METHODS: The minimum inhibitory concentration (MIC) values obtained using the dilution method were compared with the diameters of growth inhibition zones using the disk-diffusion method. Seven antifungal drugs (griseofulvin, natamycin, naftifine, clotrimazole, bifonazole, miconazole, ketoconazole) were tested with 80 fungal strains, including Trichophyton rubrum, T. mentagrophytes, Microsporum canis, and Epidermophyton floccosum.
RESULTS: The majority of fungal strains were inhibited by griseofulvin at concentrations not exceeding 10 mg/L. The least susceptible was T. mentagrophytes. The most effective drug was naftifine, and the least effective was natamycin. Naftifine inhibited 98.75% of the strains tested at a concentration not exceeding 1.0 mg/L. An increase of the MIC value was accompanied by a decrease in the growth inhibition diameter. The relation was statistically significant.
CONCLUSIONS: T. rubrum strains are more susceptible to antifungal drugs than T. mentagrophytes. Naftifine proved to be the most effective drug in dermatophytoses. Natamycin is a useful drug against yeast-like fungi but not against dermatophytes. The disk-diffusion method of fungal susceptibility assessment yields data consistent with results obtained from the dilution method and is recommended for routine use because of its simplicity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8340195     DOI: 10.1111/j.1365-4362.1993.tb02844.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  8 in total

Review 1.  Antifungal susceptibility testing: practical aspects and current challenges.

Authors:  J H Rex; M A Pfaller; T J Walsh; V Chaturvedi; A Espinel-Ingroff; M A Ghannoum; L L Gosey; F C Odds; M G Rinaldi; D J Sheehan; D W Warnock
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

2.  Evaluation of disk diffusion method for determining eberconazole susceptibility of dermatophytes and influence of culture medium.

Authors:  Belkys Fernández-Torres; Isabel Inza; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

3.  A random comparative study of terbinafine versus griseofulvin in patients with tinea capitis in Western China.

Authors:  S Deng; H Hu; P Abliz; Z Wan; A Wang; W Cheng; R Li
Journal:  Mycopathologia       Date:  2011-06-24       Impact factor: 2.574

4.  Agar-based disk diffusion assay for susceptibility testing of dermatophytes.

Authors:  E I Nweze; P K Mukherjee; M A Ghannoum
Journal:  J Clin Microbiol       Date:  2010-07-28       Impact factor: 5.948

5.  Occurrence of dermatomycoses and in-vitro therapeutic efficacy of three antifungal drugs on the growth of Epidermophyton floccosum.

Authors:  V A Awoderu; G C Nebo; V O Otudero
Journal:  Mycopathologia       Date:  2003       Impact factor: 2.574

6.  In vitro activities of the new antifungal drug eberconazole and three other topical agents against 200 strains of dermatophytes.

Authors:  Belkys Fernández-Torres; Isabel Inza; Josep Guarro
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

7.  Amorolfine 5% Nail Lacquer Exhibits Potent Antifungal Activity Compared to Three Acid-Based Devices Indicated for the Treatment of Onychomycosis: An In Vitro Nail Penetration Assay.

Authors:  Mahmoud Ghannoum; Karine Sevin; Marlis Sarkany
Journal:  Dermatol Ther (Heidelb)       Date:  2016-02-01

8.  Antifungal susceptibility and virulence factors of clinically isolated dermatophytes in Tehran, Iran.

Authors:  Mohammad Ali Afshari; Masoomeh Shams-Ghahfarokhi; Mehdi Razzaghi-Abyaneh
Journal:  Iran J Microbiol       Date:  2016-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.